{
    "2019-11-22": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Pfizer Is the Dowâ€™s Worst Stock. A New Strategy Makes It Worth Another Look.",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Dow",
                        "Worst Stock",
                        "New Strategy"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Pharma Stock Roundup: FDA Nod to NVS & AZN's Drugs, BMY-CELG Merger Closes",
                "features": {
                    "keywords": [
                        "FDA",
                        "NVS",
                        "AZN",
                        "Drugs",
                        "BMY-CELG",
                        "Merger"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}